Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
These guys have received a notice of allowance from @JPO_JPN in relation to their Immunomodulator I patent application related to the use of p38 MAPK inhibitors for the treatment of severe #influenza. Strengthening their intellectual property protection in the territory!!
https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/w6m9gqx
MASSIVE vote of confidence this...
All shareholders and Directors aligned and motivated to see the shareprice gain traction higher up
No fees or salaries to pay for 3 months as all directors take stock instead of salary
All directors have agreed to subscribing for shares in ECR, on the same terms as the new directors and investors to preserve cash (maybe allowing them to utilise incoming funds for working cap, new opportunities and it's existing P/f)
The new director fee is £22.5k a quarter, and the shares are intended to be issued at the end of the quarter assuming the price is above the recent placing.
After that the directors will be issued shares at the 14 day VWAP or at any new issue price during the proceeding quarter i.e a trailing price as it rises or at any further new issue price.
Shares will never be issued BELOW the initial placing price when new management came Into the company.
So all investors and new management are aligned!
Let the turnaround story begin!!!
"I’m delighted to share that the patent opposition to one of our European patents (Immunomodulator I) that was filed by a third party, is to be withdrawn. In the pharmaceutical industry it is not unusual for patents to be challenged. However, following our engagement with the opposing party, Poolbeg has reached an amicable conclusion in relation to the patent dispute without any financial compensation between the parties. This has resulted in the opposing party agreeing to withdraw its opposition to the Immunomodulator I European patent and agreeing not to challenge any of Poolbeg’s Immunomodulator I or Immunomodulator II patents in the future.This is a very favorable resolution and a positive outcome for Poolbeg, we have full confidence in the strength and validity of our patent portfolio and will continue to broaden and defend our intellectual property going forward"
Cathal Friel (Chairman and co-founder)
https://www.londonstockexchange.com/news-article/POLB/immunomodulator-i-patent-opposition-withdrawal/16129437
Congratulations to CEO, Yamin 'Mo' Khan, for being shortlisted for the #Entrepreneur of the Year Award at the @AIM_Awards 2023.
Results to be released on Thursday 12 October.
Nominations overview:
https://www.aim-awards.co.uk/nominations-overview/
You can access the #research notes directly on the Poolbeg Pharma website.
Read the research notes by @CavendishCF, @_singercm and @proactive_UK through @research_tree 💻
https://www.poolbegpharma.com/investors/analyst-research/
“…After concluding a £10m placing to fund continued exploration, and new results expected soon, is the share due another run?…”
https://total-market-solutions.com/2023/09/predator-oil-gas-holdings-plc/
The #HVO team are delighted to be attending the 9th @ESWInfluenza Conference in Valencia on 17-20 September
https://eswiconference.org/symposium/SPS01/
Does this help. This is the way i see it...
It's a purely a procedural process allowing the Company to reduce the nominal value of its shares from 1p to 0.1p WITHOUT diluting existing shareholders as the Companies Act prohibits companies from issuing shares at below the nominal value.
It'll have ZERO impact on shareholders - no new ordinary shares are being issued.
The reason for it is to allow the company to take advantage of the general authority to issue new shares (up to 20% of share capital only) it's requesting at the AGM - that means the Company is able to be more agile as and when it wants to raise some cash.
This is all subject to a shareholder vote at the AGM so is entirely in shareholder control.
There's no impact on existing warrants currently issued by the company, which have a 5p/share exercise price.
There's nothing fishy going on!
Amy more thoughts or questions please send to me and i can try and pass on to the BOD if thats helps?
david burton.tms@gmail.com
“…Elsewhere, @hVIVO_UK settled at a six-month high of 19½p, after rising 1¼p, or 6.9 per cent, as the Aim-listed drugs trial operator hailed “another period of excellent growth”
https://www.thetimes.co.uk/article/6e0736b0-518f-11ee-abb5-ce4135341f1b?shareToken=df86eb0535d704f9d7857298a95f2f39
In case you missed last nights' @investormeetco presentation by the HVO CEO & CFO on the Interim Results H1 2023, you can now watch the full recording here:
https://www.youtube.com/watch?v=ut3Tv9-m7w4
Terrific write up in the @IChronicle for @hVIVO_UK
“…Another upgrade makes this takeover target a buy. #HVO has upgraded guidance and there is increasing bid activity in the sector…”
✅First-half cash profit rises 126 per cent to £5.2mn
✅52 per cent higher revenue of £27.3mn
✅Cash profit margin expands from 12.6 to 19.1 per cent
✅Net cash has doubled to £31.3mn (4.6p) in past 12 months
✅Analysts upgrade 2023 and 2024 EPS estimates by 62 per cent and 46 per cent
https://www.investorschronicle.co.uk/ideas/2023/09/12/bumper-upgrades-make-this-takeover-target-a-buy/
DM me on Twitter / X for full note if required. @Davidburton1971
“…With a low operational burn and strong financial discipline, we ended the period with a robust financial position of £14.1m cash…”
Cathal Friel
Chairman and Co-Founder
https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/x2el0lx
“…We’re in a really, really excellent financial position and we’re a small board, and we can manoeuvre quite quickly. We’re quite dynamic in the way we operate…”
Video below:
https://youtu.be/TjgqAhUxz14
✅ Significant financial & operational growth in H1 23
✅Increasing no. & size of challenge trials
✅Facilities expansion; increasing revenue potential & enhancing long term margins
✅Positive outlook
https://m.youtube.com/watch?v=PXrCvG-Tkyk
Interim Results #HVO
↗️Revenue up 52% = £27.3m
📈EBITDA >doubled = £5.2m
💵Net cash = £31.3m at 30 June
💪FY23 Revenue upgrade = £55m
⬆️ FY23 EBITDA margin upgrade = c.19%
📣Nominal Annual Dividend = details to be announced with FY23 audited results
https://polaris.brighterir.com/public/hvivo/news/rns/story/rgz9g3w
The HVO VP of Regulatory Affairs featured in @pharmafocusasia on how Human Challenge Trials can establish early efficacy for #vaccines & #therapeutics for infectious disease & can be a tool to enhance the success rate for clinical development
(pg 56-59)
https://www.pharmafocusasia.com/latest-ebook